- Report
- March 2024
- 195 Pages
Global
From €3277EUR$3,374USD£2,800GBP
€3641EUR$3,749USD£3,111GBP
- Report
- February 2024
- 175 Pages
Global
From €4856EUR$5,000USD£4,149GBP
- Report
- October 2023
- 178 Pages
Global
From €4759EUR$4,900USD£4,066GBP
- Report
- July 2020
- 416 Pages
Global
From €4720EUR$4,860USD£4,033GBP
- Report
- November 2018
- 207 Pages
Global
From €4808EUR$4,950USD£4,107GBP
- Report
- June 2020
- 112 Pages
Global
From €4613EUR$4,750USD£3,941GBP
- Report
- August 2022
- 34 Pages
Global
From €1311EUR$1,350USD£1,120GBP
- Report
- March 2024
- 132 Pages
Global
From €923EUR$950USD£788GBP
The Apoptosis Assay market within the context of Oncology Drugs is a specialized field of research that focuses on the study of programmed cell death. Apoptosis assays are used to measure the efficacy of oncology drugs in inducing apoptosis, or cell death, in cancer cells. These assays are used to evaluate the effectiveness of oncology drugs in killing cancer cells, as well as to identify potential side effects of the drugs. Apoptosis assays are also used to study the mechanisms of action of oncology drugs, and to identify biomarkers that can be used to predict drug response.
Some companies in the Apoptosis Assay market within the context of Oncology Drugs include Bio-Rad Laboratories, Promega Corporation, Merck KGaA, Cell Signaling Technology, Inc., and Abcam plc. Show Less Read more
